不同VATS切除术式对T1期NSCLC患者手术相关临床指标、肺功能及炎症反应水平的影响

目的:探讨VATS肺段和VATS肺叶切除术式对T1期NSCLC患者手术相关临床指标、肺功能及炎症反应水平的影响。方法:研究对象选取我院2015年6月至2017年6月收治T1期NSCLC患者共130例，根据手术方案不同分为肺叶切除组（65例）和肺段切除组（65例），分别采用VATS肺段和VATS肺叶切除术式治疗；比较两组患者手术相关临床指标水平、手术前后肺功能指标、炎症反应实验室指标水平及术后并发症发生率。结果:肺叶切除组患者手术操作时间和术中失血量均显著优于肺段切除组（P<0.05）；肺段切除组患者术后引流量、术后引流时间及总住院时间均显著优于肺叶切除组（P<0.05）；两组患者淋巴结数量比较差异无统计学意义（P>0.05）；肺段切除组患者术后肺功能指标水平均显著高于肺叶切除组（P<0.05）；肺段切除组患者术后炎症反应实验室指标水平均显著低于肺叶切除组（P<0.05）；两组患者术后并发症发生率比较差异无统计学意义（P>0.05）。结论:相较于VATS肺叶切除术式，VATS肺段切除术式治疗T1期NSCLC可有效加快病情康复进程，保护肺部通气功能，并有助于抑制术后全身炎症反应；而VATS肺叶切除术式则能够缩短手术用时，降低医源性创伤程度。     

Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC

IntroductionWe retrospectively analyzed the effects of crizotinib on serum creatinine and creatinine-based estimated glomerular filtration rate (eGFR) in patients with anaplastic lymphoma kinase–positive advanced NSCLC across four trials (NCT00585195, NCT00932451, NCT00932893, and NCT01154140).MethodsChanges from baseline data in serum creatinine and eGFR, calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine-based equation, were assessed over time. eGFR was graded using standard chronic kidney disease criteria.ResultsMedian serum creatinine increased from 0.79 mg/dL at baseline to 0.93 mg/dL after 2 weeks of treatment (median percentage increase from baseline, 21.2%), was stable from week 12 (0.96 mg/dL) to week 104 (1.00 mg/dL), and decreased to 0.90 mg/dL at 28 days after last dose (median percentage increase from baseline, 13.1%). Median eGFR decreased over time (96.42, 80.23, 78.06 and 75.45 mL/min/1.73 m² at baseline, week 2, week 12, and week 104, respectively) and increased to 83.02 mL/min/1.73 m² at 28 days after the last dose. Median percentage decrease from baseline was 14.9%, 17.0%, and 10.4% at week 2, week 12, and 28 days after last dose of crizotinib, respectively. Overall, 12.6% of patients had a shift from eGFR grade less than or equal to 3a (≥45 mL/min/1.73 m²) at baseline to greater than or equal to 3b (<45 mL/min/1.73 m²) post-baseline.ConclusionsCrizotinib resulted in a decline in creatinine-based estimates of renal function mostly over the first 2 weeks of treatment. However, there was minimal evidence of cumulative effects with prolonged treatment and these changes were largely reversible following treatment discontinuation, consistent with previous reports suggesting this may be predominantly an effect on creatinine secretion as opposed to true nephrotoxicity.